AU2003280191A1 - Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia - Google Patents

Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia

Info

Publication number
AU2003280191A1
AU2003280191A1 AU2003280191A AU2003280191A AU2003280191A1 AU 2003280191 A1 AU2003280191 A1 AU 2003280191A1 AU 2003280191 A AU2003280191 A AU 2003280191A AU 2003280191 A AU2003280191 A AU 2003280191A AU 2003280191 A1 AU2003280191 A1 AU 2003280191A1
Authority
AU
Australia
Prior art keywords
combination
lymphocytic leukemia
chronic lymphocytic
nitrogen mustard
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003280191A
Other languages
English (en)
Inventor
Raquel Silvia Aloyz
Lawrence Carl Panasci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jewish General Hospital
Original Assignee
Jewish General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jewish General Hospital filed Critical Jewish General Hospital
Publication of AU2003280191A1 publication Critical patent/AU2003280191A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2003280191A 2002-11-12 2003-11-10 Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia Abandoned AU2003280191A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42548102P 2002-11-12 2002-11-12
US60/425,481 2002-11-12
PCT/IB2003/005454 WO2004043466A1 (en) 2002-11-12 2003-11-10 Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia

Publications (1)

Publication Number Publication Date
AU2003280191A1 true AU2003280191A1 (en) 2004-06-03

Family

ID=32312996

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003280191A Abandoned AU2003280191A1 (en) 2002-11-12 2003-11-10 Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia

Country Status (11)

Country Link
US (2) US20060122186A1 (enExample)
EP (1) EP1578426B1 (enExample)
JP (1) JP4854198B2 (enExample)
CN (1) CN100475212C (enExample)
AT (1) ATE468855T1 (enExample)
AU (1) AU2003280191A1 (enExample)
BR (1) BR0316126A (enExample)
CA (1) CA2504665C (enExample)
DE (1) DE60332762D1 (enExample)
ES (1) ES2348140T3 (enExample)
WO (1) WO2004043466A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8501817B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
EP2240172B1 (en) * 2007-12-21 2014-03-19 Novartis AG Combination of nilotinib and chlorambucil for the treatment of chronic lymphocytic leukemia
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN105997981A (zh) * 2016-06-13 2016-10-12 崔坤峰 苯丁酸氮芥的药物组合物及其抗抑郁的医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506257A (en) * 1992-03-26 1996-04-09 University Of British Columbia Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
CN1088777A (zh) * 1992-12-18 1994-07-06 丛繁滋 用于癌病灶直接给药的化疗药物制剂的制备方法
EP1509219A1 (en) * 2002-05-13 2005-03-02 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure

Also Published As

Publication number Publication date
BR0316126A (pt) 2005-09-27
WO2004043466A1 (en) 2004-05-27
US20060122186A1 (en) 2006-06-08
US8492383B2 (en) 2013-07-23
DE60332762D1 (de) 2010-07-08
ATE468855T1 (de) 2010-06-15
CA2504665A1 (en) 2004-05-27
US20090312290A1 (en) 2009-12-17
CN1711090A (zh) 2005-12-21
CA2504665C (en) 2012-12-18
ES2348140T3 (es) 2010-11-30
CN100475212C (zh) 2009-04-08
JP2006508118A (ja) 2006-03-09
EP1578426B1 (en) 2010-05-26
JP4854198B2 (ja) 2012-01-18
EP1578426A1 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
WO2002034727A3 (en) Treatment of gastrointestinal stromal tumors
MY128664A (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
IL164678A (en) High-drug tablet containing 4– (4-methylpiprazine – 1-ylamethyl) -n - [(4-methyl-3– (4-pyridin-3-il) pyrimidine-2-ylamino) phenyl] -benzamide or compatible salt Its pharmaceutical and process for its preparation
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
AU2003280191A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
ATE339197T1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten
PL370264A1 (en) Treatment of rheumatoid arthritis using imatinib
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
GEP20074051B (en) Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
AU2003244922A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
IL164018A0 (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serineprotease factor xa
WO2004026930A3 (en) The method for reducing inflammation using sti-571 or its salt
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
WO2004103374A3 (en) Imatinib combinations for head and neck cancers
WO2005113526A3 (en) Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
HK1097535A (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase